Management of Iron Overload in Infants and Toddlers With Diamond–Blackfan Anemia Syndrome: A French–Italian Study - Takeaways - MDSpire
Coming Soon: Introducing MDSpire News. Learn more
Conexiant’s news site is now MDSpire News. Learn more

Approaches to Managing Iron Overload in Young Children With Diamond–Blackfan Anemia Syndrome: Insights from a French–Italian Investigation

  • By

  • Francesca Torchio

  • Baptiste Lecalvez

  • Emanuela Garelli

  • Coralie Mallebranche

  • Adriana Carando

  • Marie-Pierre Castex

  • Nathalie Garnier

  • Marco Zecca

  • Nathalie Aladjidi

  • Elisa Bertoni

  • Arthur Sterin

  • Maria Licciardello

  • Anne Sirvent

  • Antonella Sau

  • Isabelle Marie

  • Benedicte Bruno

  • Lydie M. Da Costa

  • Franca Fagioli

  • Paola Quarello

  • Thierry Leblanc

  • May 11, 2026

Share

  • 1

    Diamond–Blackfan Anemia Syndrome (DBAS) is a rare disorder affecting 5–10 cases per million live births, characterized by pure red cell aplasia and cancer predisposition.

  • 2

    Approximately 90% of DBAS patients require regular blood transfusions within their first year, leading to chronic iron overload.

  • 3

    Iron chelation therapy is critical for managing iron overload in DBAS, yet no specific guidelines exist for initiating treatment in infants and toddlers.

  • 4

    Three chelating agents are available for DBAS: deferoxamine, deferasirox, and deferiprone, each with specific limitations for use in young children.

  • 5

    A retrospective study was conducted to evaluate iron chelation practices in DBAS patients under three years of age from French and Italian cohorts.

Original Source(s)

Related Content